<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969449</url>
  </required_header>
  <id_info>
    <org_study_id>14566</org_study_id>
    <nct_id>NCT00969449</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan</brief_title>
  <official_title>An Open Label, Randomized, Two-Way Crossover Trial to Compare the Pharmacokinetic Parameters of an Extended- Release Naproxen Sodium Tablet Relative to Naprelan® Tablets Following Single Dose Administration Under Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetic profile of the proposed extended- release tablet of naproxen&#xD;
      sodium 660 mg relative to two tablets of Naprelan 500 mg following single dose administration&#xD;
      for 36 hours under fasted conditions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of Naproxen Sodium ER 660 mg compared to Naprelan</measure>
    <time_frame>36 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety and tolerability of the extended release naproxen sodium</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess additional pharmacokinetic parameters</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium, (BAY H6689)</intervention_name>
    <description>One dose of Naproxen sodium extended release 660 mg under fasting conditions</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naprelan, (BAY H6689)</intervention_name>
    <description>One dose of Naprelan 500 mg (2 tablets) under fasting conditions</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects between 18 to 55 years of age inclusive with a Body&#xD;
             Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight &gt;50 kg (110&#xD;
             lbs)&#xD;
&#xD;
          -  Results of screening and clinical laboratory tests are within normal range or&#xD;
             considered not clinically significant by the Principal Investigator or Sponsor&#xD;
&#xD;
          -  Female subjects of childbearing potential must be using a medically acceptable form of&#xD;
             birth control for at least 1 month prior to screening (3 months on oral&#xD;
             contraceptives), e.g., oral or patch contraceptives, intrauterine device,&#xD;
             Depo-Provera®, or a double barrier and have a negative pregnancy test at Screening and&#xD;
             Day 0 for each Dosing Period. Female subjects of non-childbearing potential must be&#xD;
             amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy&#xD;
&#xD;
          -  Be willing to participate in all scheduled visits, treatment plan, laboratory tests&#xD;
             and other trial procedures according to the clinical protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to aspirin (ASA), naproxen sodium, or acetaminophen, and&#xD;
             similar pharmacological agents or components of the products&#xD;
&#xD;
          -  Females who are pregnant or lactating&#xD;
&#xD;
          -  Loss of blood in excess of 500 ml within 56 days of the first dose of trial treatment&#xD;
             (e.g., donation, plasmapheresis or injury)&#xD;
&#xD;
          -  History of gastrointestinal bleeding or perforation, related to previous NSAID&#xD;
             therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct&#xD;
             episodes of proven ulceration or bleeding)&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases&#xD;
             or malignancies&#xD;
&#xD;
          -  Positive alcohol or drug test at Screening and on Day 0 of each Dosing Period&#xD;
&#xD;
          -  Have taken any medications (except acceptable forms of birth control) within 10 days&#xD;
             prior to dosing or throughout the trial, unless in the opinion of the Investigator and&#xD;
             the Sponsor, the medication will not interfere with the trial procedures, data&#xD;
             integrity, or compromise the safety of the subject&#xD;
&#xD;
          -  Have taken ASA, ASA-containing products, acetaminophen (acetyl-para-amino-phenol or&#xD;
             APAP) or any NSAID (OTC or prescription) 7 days prior to dosing or during the&#xD;
             treatment period, other than trial treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Naproxen Sodium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

